Preclinical

W. L. Gore & Associates

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate

Lead Product(s): Stem cell-derived pancreatic islet cell progenitors

Therapeutic Area: Endocrinology Product Name: PEC-Encap

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: ViaCyte Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 05, 2020

Details:

Parties have signed an agreement covering the next phase of their ongoing collaboration focused on the development of ViaCyte's Encaptra® Cell Delivery System enabled by proprietary Gore advanced material technologies.

Enthera Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Enthera Pharmaceuticals Raises €28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD

Lead Product(s): Ent001

Therapeutic Area: Endocrinology Product Name: Ent001

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Sofinnova Partners

Deal Size: $33.1 million Upfront Cash: Undisclosed

Deal Type: Series A Financing July 28, 2020

Details:

Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.

MBX Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

MBX Debuts with $35M to Bankroll Rare Endocrine Pipeline

Lead Product(s): Undisclosed

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Frazier Healthcare Partners

Deal Size: $34.6 million Upfront Cash: Undisclosed

Deal Type: Series A Financing July 27, 2020

Details:

Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets.

University of Pittsburgh

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

NIH Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex

Lead Product(s): GPX-002

Therapeutic Area: Endocrinology Product Name: GPX-002

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $2.5 million Upfront Cash: Undisclosed

Deal Type: Funding July 21, 2020

Details:

The grant will assist Dr. Gittes’s development for his research project titled, “Alpha Cell Conversion to Beta Cells in Non-human Primates” and will build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes.

PreveCeutical Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity

Lead Product(s): siRNA

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

The company has identified a promising modified delivery vector ready for possible pre-clinical experiments based on stable siRNA (small interfering ribonucleic acid) incorporation within the delivery vehicle.

ProLynx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

ProLynx announces SBIR Arant Award to Develop Long-Ating Parathyroid Hormone for Hypo-Parathyroidism

Lead Product(s): PTH(1-34)

Therapeutic Area: Endocrinology Product Name: PTH(1-34)

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: National Institute of Health

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding July 07, 2020

Details:

The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism.

Follicum AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Follicum AB Receives Notice of Allowance From the US Patent Office for the Protection of the Company’s Peptides Developed for the Treatmen...

Lead Product(s): Peptide

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2020

Details:

The application is directed to new peptides from the company’s two peptide classes, and their use in the treatment of diabetes and its complications.

Sun Pharmaceutical Industries Limited

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Sun Pharma Announces Pre-Clinical Data on GL0034 to Treat Type 2 Diabetes and Obesity

Lead Product(s): GL0034

Therapeutic Area: Endocrinology Product Name: GL0034

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

Pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters and a marked and meaningful reduction in triglyceride levels.

Alizé Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Alize Pharma 3 Announces Rebranding to Amolyt Pharma

Lead Product(s): AZP-3601

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

W. L. Gore & Associates

ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate

Enthera Pharmaceuticals

Enthera Pharmaceuticals Raises €28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD

MBX Biosciences

MBX Debuts with $35M to Bankroll Rare Endocrine Pipeline

University of Pittsburgh

NIH Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex

PreveCeutical Medical

PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity

ProLynx

ProLynx announces SBIR Arant Award to Develop Long-Ating Parathyroid Hormone for Hypo-Parathyroidism

Follicum AB

Follicum AB Receives Notice of Allowance From the US Patent Office for the Protection of the Company’s Peptides Developed for the Treatmen...

Sun Pharmaceutical Industries Limited

Sun Pharma Announces Pre-Clinical Data on GL0034 to Treat Type 2 Diabetes and Obesity

Alizé Pharma

Alize Pharma 3 Announces Rebranding to Amolyt Pharma